Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome Inc.

In a report released today, Chad Messer from Lake Street maintained a Buy rating on Immunome, with a price target of $22.00. Messer covers the Heal...

Market Cap	$1.41B	P/E Ratio	N/A
52W High	$20.80	52W Low	$5.15
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-32.7%	52W Position	92.1%
Overall Score	60	Value Score	50
Quality Score	47	Technical Score	83

EPS Current Est	$-2.33	EPS Next Est	$-2.56
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMNM	$19.57	+0.41%	1.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMNM	$19.57	+0.4%	1.42M
3
4
5
6

IMNM

IMNM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Immunome Inc. Data in Excel

Get Immunome Inc. Data in Excel